|
|
Welcome to the COVID-19 Vaccine Partner Newsletter! Here you'll find the latest news and information on COVID-19 vaccine related topics.
|
|
Q: WHAT IS A COVID-19 VACCINE BEYOND-USE DATE (BUD) DATE?
A: There are two important dates to know when it comes to COVID-19 vaccines.
The COVID-19 vaccine expiration date is the final day on which the batch or vial of the COVID-19 vaccine can be administered. The expiration date is determined by the manufacturer and is the final day that the manufacturer guarantees the full potency and safety of the vaccine.
The COVID-19 BUD is the last day that the COVID-19 vaccine can be safely used after it has been transitioned between storage states (thawed, refrigerated, etc.) or altered (diluted, drawn up for administration, etc.) for patient use.
What to Know
- When preparing vaccine, the health care provider should calculate the BUD, then write the exact date/time on the vial.
- The BUD is determined based on the storage conditions and the time a vial is first punctured for COVID-19 vaccines.
- The beyond-use date replaces the manufacturer's expiration date.
Expired and beyond-use vaccines and diluents should NEVER be administered and should be discarded immediately.
For more information on expiration dates, beyond-use dates, and beyond-use time, please visit the CDC.
COVID-19 vaccine brand BUDs:
Pfizer-BioNTech COVID-19 Vaccine
Moderna COVID-19 Vaccine
Novavax COVID-19 Vaccine
Janssen COVID-19 Vaccine
|
|
IMPLEMENTATION GRANTS FOR PROJECTS AIMED AT VACCINE UPTAKE AND CONFIDENCE
The National Association of School Nurses (NASN) in collaboration with the Institute of Educational Leadership (IEL) and with generous support from Kaiser Permanente, is pleased to announce the second Champions for School Health funding opportunity for projects designed to increase access to and confidence in the pediatric COVID-19 vaccine and school-required vaccines, particularly in under-resourced communities.
In this funding cycle, awards between $10,000 - $30,000 will be given. Awards are limited to grantees within the Kaiser Permanente market – California, Colorado, Georgia, Hawaii, Maryland, Oregon, Virginia, Washington, and the District of Columbia. The deadline for submission of grant applications is 5 p.m. EDT on September 30, 2022.
View the complete announcement with application instructions.
Go to the application portal. Instructions for creating a NASN account and accessing the application portal are included at the end of this email.
View NASN's Champions for School Health Resource page.
If you have any questions, please contact Deborah D’Souza-Vazirani at dvazirani@nasn.org or Stephanye White at swhite@nasn.org.
|
|
REPORT ON SAFETY MONITORING OF FIRST MRNA BOOSTER FOR 12+, IMMUNOCOMPROMISED
On July 15, the Morbidity and Mortality Weekly Report (MMWR) published findings from a study on the safety of first booster doses among the immunocompromised.
Persons with moderate to severe immunocompromising conditions are at risk for severe COVID-19, and their immune response to COVID-19 vaccination might not be as robust as the response in persons who are not immunocompromised. The Advisory Committee on Immunization Practices (ACIP) recommends that immunocompromised persons aged ≥12 years complete a 3-dose primary mRNA COVID-19 vaccination series followed by a first booster dose (dose 4) ≥3 months after dose 3 and a second booster dose (dose 5) ≥4 months after dose 4.
The findings showed that among presumed immunocompromised persons aged ≥12 years, local and systemic reactions were less frequently reported to v-safe after mRNA booster (dose 4) than after primary series dose 3. Only 17 serious adverse events were reported to the Vaccine Adverse Event Reporting System (VAERS).
Serious adverse events after mRNA booster (dose 4) are rare. Immunocompromised persons aged ≥12 years should receive a first booster ≥3 months after a 3-dose primary COVID-19 vaccination series and a second booster ≥4 months after the first booster.
|
|
CDC RELEASES STUDY ON SECOND BOOSTER DOSE FOR THOSE 50 AND OLDER
Similar to the study mentioned above, another safety monitoring study was conducted on second COVID-19 vaccine booster doses for those aged 50 and older. The results published in MMWR on July 29, found that among persons aged ≥50 years who received mRNA COVID-19 vaccination, injection site and systemic reactions were less frequent after a second booster dose than after the first booster dose. 95% of 8,515 events reported to VAERS were nonserious.
ACIP recommends that all persons aged ≥5 years receive one booster dose of a COVID-19 vaccine after completion of their primary series; adults aged ≥50 years and persons aged ≥12 years with moderate to severe immunocompromise might receive a second booster ≥4 months after their first booster dose.
|
|
CHOP PUBLISHES NEW INFOGRAPHIC FOR COVID-19 DISEASE VS. VACCINE
The Children’s Hospital of Philadelphia is a valuable resource for many topics, including vaccines. Recently, they updated their infographic on COVID-19 which gives a brief overview of signs and symptoms of COVID-19 as well as the common side effects of the vaccine.
This is a great resource to share with your patients and have available in your office/clinic.
To see more information on COVID-19 vaccines from CHOP, please visit their website.
|
|
NEW REPORTS ON LONG COVID
This week the Biden–Harris Administration released two new reports on Long COVID to support patients and further research. In April, President Joe Biden issued a Memorandum on Addressing the Long-Term Effects of COVID-19, which called for the creation of two reports. Within 120 days, the U.S. Department of Health and Human Services (HHS), leading a whole-of-government response, developed the following reports that together, pave an actionable path forward to address Long COVID and associated conditions.
Additional information related to the announcement and release of the reports:
|
|
REMINDER: COVID-19 VACCINE TEMP LOG SUBMISSION
Quick reminder, COVID-19 vaccine temperature logs are due the first week of the month (for the previous month) via REDCap Survey submission. On the 1st of every month, a REDCap survey invitation is sent directly to COVID-19 vaccine providers via email. These surveys must be responded to by the 15th of the month to prevent any unwanted pausing to COVID-19 vaccine ordering and transfers.
If you are a Childhood Vaccine Program (CVP) provider that uses the same storage equipment for your CVP and Adult Vaccine Program (AVP) vaccines, you will need to continue to follow the submission requirements for those programs in conjunction with COVID-19 Vaccine Program REDCap Survey requirement. We ask that you submit your temperature log for review via the REDCap Survey link sent out each month. This can also be the same temperature logs for CVP units that are housing COVID-19 vaccine. If you are not receiving the monthly survey, please reach out to us via email as this may require updates to your facilities contacts.
For more information regarding the temperature log submission requirements for the COVID-19 Vaccine Program, please refer to the COVID-19 Vaccine Program Temperature Log Monthly Requirement Guide or email us at COVID.Vaccine@doh.wa.gov with any questions.
As always, thank you for your partnership!
|
|
MODERNA SHELF-LIFE EXTENSION
Moderna COVID-19 vaccines are once again receiving a shelf-life extension by lot number. It is important to regularly monitor expiration dates of all vaccines, as dates are subject to change. Moderna vaccine vials have a QR code that, when scanned, provides the up-to-date expiration date from the manufacturer website. Check your Moderna lot number expiration dates regularly at Vial Expiration Date Lookup | Moderna COVID-19 Vaccine (EUA) (modernatx.com) and – as always – properly dispose of expired vaccine according to state and local regulations.
|
|
NOVAVAX EXPIRY PAGE NOW AVAILABLE
An Expiry Page is now available for the new Novavax COVID-19 Vaccine recently authorized for emergency use by the FDA. Novavax was approved for a 9-month refrigerated shelf-life, and all Novavax vaccine purchased by the United States government currently expires February 2023. Should this date be extended, the Novavax Expiry Page will contain all current expiration date information.
|
|
JOHNSON & JOHNSON/JANSSEN VACCINE EXPIRING THIS MONTH
A large quantity of J&J COVID-19 vaccine is expiring in August 2022. We would like to remind you to check expiration dates at Janssen COVID-19 Vaccine Expiry Checker. Again, please dispose of all expired vaccine in accordance with state and local regulations.
|
|
NOVAVAX BASICS REVIEWED
As shipments of Novavax have arrived and been distributed throughout Washington, we wanted to remind you of a few important things. As we've mentioned previously, Novavax is given as a primary series of 2 doses, at least 3 weeks apart and it is not currently authorized as a booster dose. The image above, from the CDC, also highlights key preparation and administration information.
For more information, review the Interim Clinical Considerations for the Novavax COVID-19 Vaccine | CDC.
If you are not administering Novavax but have patients who are interested in receiving it, please refer them to the nearest location using Vaccine Locator.
|
|
AIM IMMUNIZATION CHAMPION AWARD PRESENTED DURING NEXT IACW MEETING
Who will the winner be?
The Association of Immunization Managers (AIM) Immunization Champion Award is being presented virtually at the next Immunization Action Coalition of Washington (IACW) meeting at 12:00pm on August 17, 2022. The award will honor Washington state’s selected champion. The Immunization Champion Award recognizes exemplary immunization efforts in the community.
During the meeting, IACW will also present the IACW Immunization Collaborator and IACW Immunization Advocate Award winners. To see the full list of nominees, check out the Department of Health’s Immunization Champion nomination page.
Wednesday, August 17, 2022 12:00-2:00m PT
|
|
THE FUTURE OF COVID-19 VACCINES
On July 26, the White House held a summit which outlined a path towards innovative, next-generation COVID-19 vaccines and featured leaders who are on the cutting-edge of discoveries.
If you were unable to attend, you can check out a recording of the event here.
|
|
|
FOR SCHOOLS AND CHILD CARE FACILITIES
FOR LONG-TERM CARE FACILITIES
|
|
SIGN UP FOR THIS NEWSLETTER!
If you aren't already signed up for the COVID-19 Vaccine Partner Newsletter, please visit the Department of Health's email subscribers page here. Once you enter your email, on the next page expand the Immunization topic, select the COVID-19 Vaccine Partner Newsletter, and click submit.
|
|
This newsletter summarizes content from the week of July 31, 2022 and was sent out on August 5, 2022. |
|
|
|
|
